Aspire Biopharma (ASBP) Competitors $0.32 -0.03 (-9.44%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsOwnershipSEC FilingsTrendsBuy This Stock ASBP vs. PMVP, ARTV, IMA, CRVO, GNTA, PYXS, ATRA, ASRT, QNTM, and STROShould you be buying Aspire Biopharma stock or one of its competitors? The main competitors of Aspire Biopharma include PMV Pharmaceuticals (PMVP), Artiva Biotherapeutics (ARTV), Ikena Oncology (IMA), CervoMed (CRVO), Genenta Science (GNTA), Pyxis Oncology (PYXS), Atara Biotherapeutics (ATRA), Assertio (ASRT), Quantum Biopharma (QNTM), and Sutro Biopharma (STRO). These companies are all part of the "pharmaceutical products" industry. Aspire Biopharma vs. Its Competitors PMV Pharmaceuticals Artiva Biotherapeutics Ikena Oncology CervoMed Genenta Science Pyxis Oncology Atara Biotherapeutics Assertio Quantum Biopharma Sutro Biopharma Aspire Biopharma (NASDAQ:ASBP) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends. Is ASBP or PMVP more profitable? Aspire Biopharma's return on equity of 0.00% beat PMV Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Aspire BiopharmaN/A N/A -508.70% PMV Pharmaceuticals N/A -32.54%-29.59% Does the media favor ASBP or PMVP? In the previous week, Aspire Biopharma had 1 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 1 mentions for Aspire Biopharma and 0 mentions for PMV Pharmaceuticals. Aspire Biopharma's average media sentiment score of 0.00 equaled PMV Pharmaceuticals'average media sentiment score. Company Overall Sentiment Aspire Biopharma Neutral PMV Pharmaceuticals Neutral Which has more risk and volatility, ASBP or PMVP? Aspire Biopharma has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, PMV Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Do analysts recommend ASBP or PMVP? PMV Pharmaceuticals has a consensus price target of $5.50, indicating a potential upside of 261.84%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe PMV Pharmaceuticals is more favorable than Aspire Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00PMV Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in ASBP or PMVP? 19.2% of Aspire Biopharma shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 48.0% of Aspire Biopharma shares are owned by company insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better valuation and earnings, ASBP or PMVP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAspire BiopharmaN/AN/A-$12.54MN/AN/APMV PharmaceuticalsN/AN/A-$58.71M-$1.18-1.29 SummaryPMV Pharmaceuticals beats Aspire Biopharma on 6 of the 10 factors compared between the two stocks. Get Aspire Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ASBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ASBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASBP vs. The Competition Export to ExcelMetricAspire BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.52M$3.02B$5.57B$9.48BDividend YieldN/A2.42%4.31%4.13%P/E RatioN/A5.8618.7821.62Price / SalesN/A306.36441.7495.96Price / CashN/A42.1735.8458.51Price / Book-0.157.818.085.58Net Income-$12.54M-$54.52M$3.26B$265.35M7 Day Performance-25.16%-0.87%-0.73%-0.89%1 Month Performance9.69%13.63%5.52%4.98%1 Year PerformanceN/A11.57%28.79%23.50% Aspire Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASBPAspire BiopharmaN/A$0.32-9.4%N/AN/A$17.52MN/A0.00N/AGap DownPMVPPMV Pharmaceuticals2.8164 of 5 stars$1.40-1.4%$5.50+292.9%+1.4%$73.77MN/A-1.1950ARTVArtiva Biotherapeutics2.1485 of 5 stars$2.83-5.7%$17.80+529.0%-72.3%$73.09M$250K0.0081News CoverageEarnings ReportUpcoming EarningsGap DownIMAIkena Oncology3.4998 of 5 stars$17.28-3.5%$35.50+105.4%-15.7%$71.96M$9.16M-2.2570Positive NewsAnalyst RevisionCRVOCervoMed2.8787 of 5 stars$8.83+7.0%$21.50+143.5%-24.6%$71.80M$9.74M-4.054Upcoming EarningsGap DownGNTAGenenta Science2.5981 of 5 stars$3.73-3.2%$25.00+571.0%-14.5%$70.35MN/A0.007News CoverageNegative NewsShort Interest ↑PYXSPyxis Oncology2.4199 of 5 stars$1.10-1.8%$9.00+718.2%-66.8%$69.38MN/A-0.6960News CoveragePositive NewsUpcoming EarningsATRAAtara Biotherapeutics3.8341 of 5 stars$11.55+0.3%$20.00+73.2%+37.3%$68.85M$199.73M-3.10330News CoverageUpcoming EarningsASRTAssertio1.8658 of 5 stars$0.71-0.5%$2.63+268.4%-39.2%$68.58M$124.96M-2.2320News CoverageUpcoming EarningsQNTMQuantum BiopharmaN/A$23.70+1.0%N/AN/A$68.24MN/A-1.48N/ANews CoverageEarnings ReportUpcoming EarningsGap UpSTROSutro Biopharma3.8407 of 5 stars$0.81+0.6%$6.11+654.9%-75.2%$68.02M$62.04M-0.27240News CoverageUpcoming Earnings Related Companies and Tools Related Companies PMVP Alternatives ARTV Alternatives IMA Alternatives CRVO Alternatives GNTA Alternatives PYXS Alternatives ATRA Alternatives ASRT Alternatives QNTM Alternatives STRO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASBP) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredGuess Who the Gvt Could Partner With Next?The Government Just Made a $400M Bet. Who's Next? A $100 trillion wealth shift is quietly underway... and t...Stansberry Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aspire Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aspire Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
